{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T01:10:33Z","timestamp":1691802633758},"reference-count":27,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jdcjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.jdiacomp.2015.06.013","type":"journal-article","created":{"date-parts":[[2015,7,4]],"date-time":"2015-07-04T18:27:56Z","timestamp":1436034476000},"page":"1248-1252","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Continuation or discontinuation of pioglitazone when starting bedtime insulin in patients with poorly controlled type 2 diabetes in an inner-city population"],"prefix":"10.1016","volume":"29","author":[{"given":"Mona","family":"Mojtahedzadeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin L.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore C.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.jdiacomp.2015.06.013_bb0010","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.2337\/dc14-S014","article-title":"Standards of medical care in diabetes--2014","volume":"37","author":"American Diabetes Association","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2015.06.013_bb0015","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1463-1326.2006.00633.x","article-title":"Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy","volume":"9","author":"Berhanu","year":"2007","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2015.06.013_bb0020","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1046\/j.1464-5491.2002.00734.x","article-title":"Combination of insulin and thiazolidinedione therapy in massively obese patients with type 2 diabetes","volume":"19","author":"Buch","year":"2002","journal-title":"Diabetic Medicine"},{"key":"10.1016\/j.jdiacomp.2015.06.013_bb0025","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.2337\/diacare.21.9.1455","article-title":"Troglitazone use in insulin-treated type 2 diabetic patients. The Troglitazone Insulin Study Group","volume":"21","author":"Buse","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2015.06.013_bb0030","series-title":"National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014","author":"Centers for Disease Control and Prevention","year":"2014"},{"key":"10.1016\/j.jdiacomp.2015.06.013_bb0035","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1210\/jc.2009-1974","article-title":"Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19)","volume":"95","author":"Charbonnel","year":"2010","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.jdiacomp.2015.06.013_bb0040","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.amjmed.2008.09.047","article-title":"Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006","volume":"122","author":"Cheung","year":"2009","journal-title":"The American Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2015.06.013_bb0045","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/S0149-2918(00)80078-8","article-title":"A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus","volume":"23","author":"Chilcott","year":"2001","journal-title":"Clinical Therapeutics"},{"key":"10.1016\/j.jdiacomp.2015.06.013_bb0050","doi-asserted-by":"crossref","first-page":"E675","DOI":"10.1503\/cmaj.112102","article-title":"Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: A meta-analysis","volume":"184","author":"Colmers","year":"2012","journal-title":"CMAJ : Canadian Medical Association journal=journal de l'Association medicale canadienne"},{"key":"10.1016\/j.jdiacomp.2015.06.013_bb0060","series-title":"Meeting the American Diabetes Association Standards of Care: An algorithmic approach to clinical care of the diabetes patient","author":"Davidson","year":"2010"},{"key":"10.1016\/j.jdiacomp.2015.06.013_bb0055","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1463-1326.2005.00499.x","article-title":"Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: Results of a double-blind, multicentre, randomized study","volume":"8","author":"Davidson","year":"2006","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2015.06.013_bb0065","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.2165\/11538100-000000000-00000","article-title":"Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: Comparison with other oral antihyperglycaemic agents","volume":"70","author":"Derosa","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.jdiacomp.2015.06.013_bb0070","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.diabres.2008.09.009","article-title":"Differences in effects of insulin glargine or pioglitazone added to oral anti-diabetic therapy in patients with type 2 diabetes: What to add--insulin glargine or pioglitazone?","volume":"82","author":"Dorkhan","year":"2008","journal-title":"Diabetes Research and Clinical Practice"},{"key":"10.1016\/j.jdiacomp.2015.06.013_bb0075","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.diabres.2010.11.028","article-title":"Insulin glargine compared to NPH among insulin-naive, U.S. inner city, ethnic minority type 2 diabetic patients","volume":"91","author":"Hsia","year":"2011","journal-title":"Diabetes Research and Clinical Practice"},{"key":"10.1016\/j.jdiacomp.2015.06.013_bb0080","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2015.06.013_bb0085","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.clinthera.2005.05.005","volume":"27","author":"Mattoo","year":"2005","journal-title":"Clinical Therapeutics"},{"key":"10.1016\/j.jdiacomp.2015.06.013_bb0090","doi-asserted-by":"crossref","first-page":"710","DOI":"10.2337\/diacare.24.4.710","article-title":"Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone","volume":"24","author":"Miyazaki","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2015.06.013_bb0095","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2337\/diacare.27.1.256","article-title":"Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association","volume":"27","author":"Nesto","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2015.06.013_bb0100","doi-asserted-by":"crossref","first-page":"61","DOI":"10.7326\/0003-4819-134-1-200101020-00014","article-title":"Nonhypoglycemic effects of thiazolidinediones","volume":"134","author":"Parulkar","year":"2001","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.jdiacomp.2015.06.013_bb0105","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.2337\/diacare.24.7.1226","article-title":"A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes","volume":"24","author":"Raskin","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2015.06.013_bb0110","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1742-1241.2002.tb11251.x","article-title":"Efficacy and safety of pioglitazone in type 2 diabetes: A randomised, placebo-controlled study in patients receiving stable insulin therapy","volume":"56","author":"Rosenstock","year":"2002","journal-title":"International Journal of Clinical Practice"},{"issue":"Suppl. I","key":"10.1016\/j.jdiacomp.2015.06.013_bb0115","first-page":"A110","article-title":"Combination therapy with pioglitazone and insulin in patients with type 2 diabetes (Abstract)","volume":"48","author":"Rubin","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2015.06.013_bb0120","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.2337\/diacare.25.10.1691","article-title":"Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes","volume":"25","author":"Strowig","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2015.06.013_bb0125","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2147\/VHRM.S5838","article-title":"Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes","volume":"6","author":"Yamanouchi","year":"2010","journal-title":"Vascular Health and Risk Management"},{"key":"10.1016\/j.jdiacomp.2015.06.013_bb0130","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.2040-1124.2010.00064.x","article-title":"Efficacy of pioglitazone on glycemic control and carotid intima-media thickness in type 2 diabetes patients with inadequate insulin therapy","volume":"2","author":"Yasunari","year":"2011","journal-title":"Journal of Diabetes Investigation"},{"key":"10.1016\/j.jdiacomp.2015.06.013_bb0135","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1056\/NEJM199211123272005","article-title":"Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus","volume":"327","author":"Yki-Jarvinen","year":"1992","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2015.06.013_bb0140","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/ATVBAHA.108.175687","article-title":"Pioglitazone inhibits the expression of inflammatory cytokines from both monocytes and lymphocytes in patients with impaired glucose tolerance","volume":"28","author":"Zhang","year":"2008","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872715002664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872715002664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:44:58Z","timestamp":1691801098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872715002664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S1056872715002664"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2015.06.013","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Continuation or discontinuation of pioglitazone when starting bedtime insulin in patients with poorly controlled type 2 diabetes in an inner-city population","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2015.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}